Keyphrases
Adjuvant Endocrine Therapy
22%
Adjuvant Trastuzumab
22%
BRAF mutation
22%
BRCA1, BRCA2
28%
Breast Cancer
28%
Breast Cancer Susceptibility Gene 1 (BRCA1)
16%
Cancer Care
22%
Cancer Survivors
9%
CHEK2
22%
CHEK2 1100delC
11%
Clinical Impact
22%
Disease-free Survival
16%
Early Triple-negative Breast Cancer
22%
Endocrine Therapy
10%
Equity Gap
22%
Germ Cells
22%
GnRH Analogue
22%
Gonadotropin-releasing Hormone
22%
HER2+ Breast Cancer
22%
Hereditary Breast Cancer
22%
Hormone Receptor-positive
22%
Hormone Receptor-positive Breast Cancer
22%
Human Epidermal Growth Factor Receptor 2 (HER2)
29%
Immune-related Adverse Events
22%
Inflammatory Breast Cancer
22%
Lifestyle Intervention
22%
Locally Advanced
22%
Neoadjuvant Chemotherapy
22%
Older People
9%
Ovarian Suppression
35%
Overall Survival
21%
Pathogenic Variants
22%
Pathological Complete Response
10%
Patient Adherence
22%
Patient Preference
22%
Pembrolizumab
22%
Postmenopausal Women
24%
Predictive Biomarker
11%
Prognostic Biomarker
22%
Real-world Treatment Patterns
22%
Relapse-free Survival
15%
Sclerosing mucoepidermoid Carcinoma with Eosinophilia
22%
Survival Outcomes
22%
Telehealth
22%
Thyroid Gland
22%
Trastuzumab Cardiotoxicity
14%
Trastuzumab Therapy
22%
Treatment Interruption
22%
Triple-negative Breast Cancer
22%
Underserved Populations
9%
Medicine and Dentistry
Adjuvant Endocrine Therapy
45%
Aromatase Inhibitor
15%
Biological Marker
22%
Breast Cancer
84%
Cardiotoxicity
8%
Delay Discounting
22%
Disease Free Survival
10%
Eosinophilia
22%
Epidermal Growth Factor Receptor 2
12%
Gamma Urogastrone
12%
Gonadorelin Derivative
22%
Gonadotropin-Releasing Hormone
22%
Hazard Ratio
5%
Hormone Receptor
67%
Hormone Therapy
45%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
50%
Inflammatory Breast Cancer
22%
Lifestyle Intervention
22%
Logistic Regression Analysis
7%
Malignant Neoplasm
24%
Mucoepidermoid Carcinoma
22%
Neoadjuvant Chemotherapy
22%
Neoplasm
9%
Odds Ratio
7%
Ovary Function
12%
Overall Survival
17%
Papillary Thyroid Cancer
6%
Patient Compliance
22%
Patient Preference
22%
Premenopause
30%
Recurrence Free Survival
13%
Recurrent Disease
7%
Tamoxifen
37%
Telehealth
22%
Trastuzumab
22%
Treatment Interruption
13%
Triple Negative Breast Cancer
22%
Underserved Population
9%
Pharmacology, Toxicology and Pharmaceutical Science
Aromatase Inhibitor
11%
Biological Marker
22%
Breast Cancer
100%
Cardiotoxicity
8%
Chemotherapy
5%
Disease Free Survival
10%
Endocrine Therapy
45%
Epidermal Growth Factor Receptor 2
10%
Gamma Urogastrone
10%
Gonadorelin Derivative
22%
Hormone Receptor
73%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
50%
Malignant Neoplasm
7%
Metastatic Breast Cancer
5%
Neoplasm
9%
Overall Survival
8%
Tamoxifen
28%
Trastuzumab
22%
Triple Negative Breast Cancer
22%